

## Continuous cultures of fused cells secreting antibody of predefined specificity

THE manufacture of predefined specific antibodies by means of permanent tissue culture cell lines is of general interest. There are at present a considerable number of permanent cultures of myeloma cells<sup>1,2</sup> and screening procedures have been used to reveal antibody activity in some of them. This, however, is not a satisfactory source of monoclonal antibodies of predefined specificity. We describe here the derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies. The cell lines are made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor. To understand the expression and interactions of the Ig chains from the parental lines, fusion experiments between two known mouse myeloma lines were carried out.

Each immunoglobulin chain results from the integrated expression of one of several *V* and *C* genes coding respectively for its variable and constant sections. Each cell expresses only one of the two possible alleles (allelic exclusion; reviewed in ref. 3). When two antibody-producing cells are fused, the products of both parental lines are expressed<sup>4,5</sup>, and although the light and heavy chains of both parental lines are randomly joined, no evidence of scrambling of *V* and *C* sections is observed<sup>4</sup>. These results, obtained in an heterologous system involving cells of rat and mouse origin, have now been confirmed by fusing two myeloma cells of the same mouse strain,

The protein secreted (MOPC 21) is an IgG1 ( $\kappa$ ) which has been fully sequenced<sup>7,8</sup>. Equal numbers of cells from each parental line were fused using inactivated Sendai virus<sup>9</sup> and samples containing  $2 \times 10^4$  cells were grown in selective medium in separate dishes. Four out of ten dishes showed growth in selective medium and these were taken as independent hybrid lines, probably derived from single fusion events. The karyotype of the hybrid cells after 5 months in culture was just under the sum of the two parental lines (Table 1). Figure 1 shows the isoelectric focusing<sup>10</sup> (IEF) pattern of the secreted products of different lines. The hybrid cells (samples c-h in Fig. 1) give a much more complex pattern than either parent (a and b) or a mixture of the parental lines (m). The important feature of the new pattern is the presence of extra bands (Fig. 1, arrows). These new bands, however, do not seem to be the result of differences in primary structure; this is indicated by the IEF pattern of the products after reduction to separate the heavy and light chains (Fig. 1B). The IEF pattern of chains of the hybrid clones (Fig. 1B, g) is equivalent to the sum of the IEF pattern (a and b) of chains of the parental clones with no evidence of extra products. We conclude that, as previously shown with interspecies hybrids<sup>4,5</sup>, new Ig molecules are produced as a result of mixed association between heavy and light chains from the two parents. This process is intracellular as a mixed cell population does not give rise to such hybrid molecules (compare m and g, Fig. 1A). The individual cells must therefore be able to express both isotypes. This result shows that in hybrid cells the expression of one isotype and idiotype does not exclude the expression of another: both heavy chain




Fig. 1 Autoradiograph of labelled components secreted by the parental and hybrid cell lines analysed by IEF before (A) and after reduction (B). Cells were incubated in the presence of <sup>14</sup>C-lysine and the supernatant applied on polyacrylamide slabs. A, pH range 6.0 (bottom) to 8.0 (top) in 4 M urea. B, pH range 5.0 (bottom) to 9.0 (top) in 6 M urea; the supernatant was incubated for 20 min at 37 °C in the presence of 8 M urea, 1.5 M mercaptoethanol and 0.1 M potassium phosphate pH 8.0 before being applied to the right slab. Supernatants from parental cell lines in: a, P1Bul; b, P3-X67Ag8; and m, mixture of equal number of P1Bul and P3-X67Ag8 cells. Supernatants from two independently derived hybrid lines are shown: c-f, four subclones from Hy-3; g and h, two subclones from Hy-B. Fusion was carried out<sup>11</sup> using  $10^4$  cells of each parental line and 4,000 haemagglutination units inactivated Sendai virus (Searle). Cells were divided into ten equal samples and grown separately in selective medium (HAT medium, ref. 6). Medium was changed every 3 d. Successful hybrid lines were obtained in four of the cultures, and all gave similar IEF patterns. Hy-B and Hy-3 were further cloned in soft agar<sup>12</sup>. L, Light; H, heavy.

and provide the background for the derivation and understanding of antibody-secreting hybrid lines in which one of the parental cells is an antibody-producing spleen cell.

Two myeloma cell lines of BALB/c origin were used. P1Bul is resistant to 5-bromo-2'-deoxyuridine<sup>4</sup>, does not grow in selective medium (HAT, ref. 6) and secretes a myeloma protein, Adj PC5, which is an IgG2A ( $\kappa$ ), (ref. 1). Synthesis is not balanced and free light chains are also secreted. The second cell line, P3-X63Ag8, prepared from P3 cells<sup>5</sup>, is resistant to  $20 \mu\text{g ml}^{-1}$  8-azaguanine and does not grow in HAT medium.

isotypes ( $\gamma 1$  and  $\gamma 2a$ ) and both  $V_H$  and both  $V_L$  regions (idiotypes) are expressed. There are no allotypic markers for the  $C_K$  region to provide direct proof for the expression of both parental  $C_K$  regions. But this is indicated by the phenotypic link between the *V* and *C* regions.

Figure 1A shows that clones derived from different hybridisation experiments and from subclones of one line are indistinguishable. This has also been observed in other experiments (data not shown). Variants were, however, found in a survey of 100 subclones. The difference is often associated with changes




Fig. 3 Isolation of an anti-SRBC antibody-secreting cell clone. Activity was revealed by a halo of haemolysed SRBC. Direct plaques given by: a, 6,000 hybrid cells Sp-1; b, clones grown in soft agar from an inoculum of 2,000 Sp-1 cells; c, recloning of one of the positive clones Sp-1/7; d, higher magnification of a positive clone. Myeloma cells ( $10^6$  P3-X67A g8) were fused to  $10^6$  spleen cells from an immunised BALB/c mouse. Mice were immunised by intraperitoneal injection of 0.2 ml packed SRBC diluted 1:10, boosted after 1 month and the spleens collected 4 d later. After fusion, cells (Sp-1) were grown for 8 d in HAT medium, changed at 1-3 d intervals. Cells were then grown in Dulbecco modified Eagle's medium, supplemented for 2 weeks with hypoxanthine and thymidine. Forty days after fusion the presence of anti-SRBC activity was revealed as shown in a. The ratio of plaque forming cells/total number of hybrid cells was 1/30. This hybrid cell population was cloned in soft agar (50% cloning efficiency). A modified plaque assay was used to reveal positive clones shown in b-d as follows. When cell clones had reached a suitable size, they were overlaid in sterile conditions with 2 ml 0.6% agarose in phosphate-buffered saline containing 25  $\mu$ l packed SRBC and 0.2 ml fresh guinea pig serum (absorbed with SRBC) as source of complement. b, Taken after overnight incubation at 37°C. The ratio of positive/total number of clones was 1/33. A suitable positive clone was picked out and grown in suspension. This clone was called Sp-1/7, and was recloned as shown in c; over 90% of the clones gave positive lysis. A second experiment in which  $10^6$  P3-X67Ag8 cells were fused with  $10^6$  spleen cells was the source of a clone giving rise to indirect plaques (clone Sp-2/3-3). Indirect plaques were produced by the addition of 1:20 sheep anti-MOPC 21 antibody to the agarose overlay.

in the ratios of the different chains and occasionally with the total disappearance of one or other of the chains. Such events are best visualised on IEF analysis of the separated chains (for example, Fig. 1h, in which the heavy chain of P3 is no longer observed). The important point that no new chains are detected by IEF complements a previous study<sup>4</sup> of a rat-mouse hybrid line in which scrambling of V and C regions from the light chains of rat and mouse was not observed. In this study, both light chains have identical  $C_H$  regions and therefore scrambled  $V_L-C_L$  molecules would be undetected. On the other hand, the heavy chains are of different subclasses and we expect scrambled  $V_H-C_H$  to be detectable by IEF. They were not observed in the clones studied and if they occur must do so at a lower frequency. We conclude that in syngeneic cell hybrids (as well as in interspecies cell hybrids) V-C integration is not the result of cytoplasmic events. Integration as a result of DNA translocation or rearrangement during transcription is also suggested by the presence of integrated mRNA molecules<sup>11</sup> and by the existence of defective heavy chains in which a deletion of V and C sections seems to take place in already committed cells<sup>12</sup>.

The cell line P3-X63Ag8 described above dies when exposed to HAT medium. Spleen cells from an immunised mouse also die in growth medium. When both cells are fused by Sendai virus and the resulting mixture is grown in HAT medium, surviving clones can be observed to grow and become established after a few weeks. We have used SRBC as immunogen, which enabled us, after culturing the fused lines, to determine the presence of specific antibody-producing cells by a plaque assay technique<sup>13</sup> (Fig. 2a). The hybrid cells were cloned in soft agar<sup>14</sup> and clones producing antibody were easily detected by an overlay of SRBC and complement (Fig. 2b). Individual clones were isolated and shown to retain their phenotype as almost all the clones of the derived purified line are capable of lysing SRBC (Fig. 2c). The clones were visible to the naked eye (for example, Fig. 2d). Both direct and indirect plaque

assays<sup>15</sup> have been used to detect specific clones and representative clones of both types have been characterised and studied.

The derived lines (Sp hybrids) are hybrid cell lines for the following reasons. They grow in selective medium. Their karyotype after 4 months in culture (Table 1) is a little smaller than the sum of the two parental lines but more than twice the chromosome number of normal BALB/c cells, indicating that the lines are not the result of fusion between spleen cells. In addition the lines contain a metacentric chromosome also present in the parental P3-X67Ag8. Finally, the secreted immunoglobulins contain MOPC 21 protein in addition to new, unknown components. The latter presumably represent the chains derived from the specific anti-SRBC antibody. Figure 3A shows the IEF pattern of the material secreted by two such Sp hybrid clones. The IEF bands derived from the parental P3 line are visible in the pattern of the hybrid cells, although obscured by the presence of a number of new bands. The pattern is very complex, but the complexity of hybrids of this type is likely to result from the random recombination of chains (see above, Fig. 1). Indeed, IEF patterns of the reduced material secreted by the spleen-P3 hybrid clones gave a simpler pattern of Ig chains. The heavy and light chains of the P3 parental line became prominent, and new bands were apparent.

The hybrid Sp-1 gave direct plaques and this suggested that it produces an IgM antibody. This is confirmed in Fig. 4 which shows the inhibition of SRBC lysis by a specific anti-IgM

Table 1 Number of chromosomes in parental and hybrid cell lines

Cell line	Number of chromosomes per cell	Mean
P3-X67Ag8	66,65,65,65,65	65
PI Bu1	Ref. 4	55
Mouse spleen cells	—	40
Hy-B (P1-P3)	112,110,104,104,102	106
Sp-1/7-2	93,90,89,89,87	90
Sp-2/3-3	97,98,96,96,94,88	95

antibody. IEF techniques usually do not reveal 19S IgM molecules. IgM is therefore unlikely to be present in the unreduced sample *a* (Fig. 3B) but  $\mu$  chains should contribute to the pattern obtained after reduction (sample *a*, Fig. 3A). The above results show that cell fusion techniques are a powerful tool to produce specific antibody directed against a predetermined antigen. It further shows that it is possible to isolate hybrid lines producing different antibodies directed against the same antigen and carrying different effector functions (direct and indirect plaque). The uncloned population of P3-spleen hybrid cells seems quite heterogeneous. Using suitable detection procedures it should be possible to isolate tissue culture cell lines making different classes of antibody. To facilitate our studies we have used a myeloma parental line which itself produced an Ig. Variants in which one of the parental chains is no longer expressed seem fairly common in the case of P1-P3 hybrids (Fig. 1*h*). Therefore selection of lines in which only the specific antibody chains are expressed seems reasonably simple. Alternatively, non-producing variants of myeloma lines could be used for fusion. We used SRBC as antigen. Three different fusion experiments were successful in producing a large number of antibody-producing cells. Three weeks after the initial fusion, 33/1,086

presented. The smaller ice the g that ills. In e also creted o new, nt the ure 3A o such ital P3 though s. The of this ion of educed simpler the P3 parent. d that which ti-IgM

11 lines  
Mean  
65  
55  
40  
106  
90  
95

antibody. IEF techniques usually do not reveal 19S IgM molecules. IgM is therefore unlikely to be present in the unreduced sample *a* (Fig. 3B) but  $\mu$  chains should contribute to the pattern obtained after reduction (sample *a*, Fig. 3A). The above results show that cell fusion techniques are a powerful tool to produce specific antibody directed against a predetermined antigen. It further shows that it is possible to isolate hybrid lines producing different antibodies directed against the same antigen and carrying different effector functions (direct and indirect plaque). The uncloned population of P3-spleen hybrid cells seems quite heterogeneous. Using suitable detection procedures it should be possible to isolate tissue culture cell lines making different classes of antibody. To facilitate our studies we have used a myeloma parental line which itself produced an Ig. Variants in which one of the parental chains is no longer expressed seem fairly common in the case of P1-P3 hybrids (Fig. 1*h*). Therefore selection of lines in which only the specific antibody chains are expressed seems reasonably simple. Alternatively, non-producing variants of myeloma lines could be used for fusion. We used SRBC as antigen. Three different fusion experiments were successful in producing a large number of antibody-producing cells. Three weeks after the initial fusion, 33/1,086



Fig. 3 Autoradiograph of labelled components secreted by anti-SRBC specific hybrid lines. Fractionation before (B) and after (A) reduction was by IEF. pH gradient was 5.0 (bottom) to 9.0 (top) in the presence of 6 M urea. Other conditions as in Fig. 1. Supernatants from: *a*, hybrid clone Sp-1/7-2; *b*, hybrid clone Sp-2/3-3; *c*, myeloma line P3-X67Ag8.




Fig. 4 Inhibition of haemolysis by antibody secreted by hybrid clone Sp-1/7-2. The reaction was in a 9-cm Petri dish with a layer of 5 ml 0.6% agarose in phosphate-buffered saline containing 1/80 (v/v) SRBC. Centre well contains 2.5 µl 20 times concentrated (v/v) culture medium of clone Sp-1/7-2 and 2.5 µl mouse serum. *a*, culture medium of clone Sp-1/7-2; *b*, sheep anti-mouse macroglobulin (MOPC 104E, Dr Feinstein); *c*, sheep anti-Adj PC-5 (IgG2a) absorbed with Adj PC-5. After overnight incubation at room temperature the plate was developed with guinea pig serum diluted 1:10 in Dulbecco's medium without serum.

clones (3%) were positive by the direct plaque assay. The cloning efficiency in the experiment was 50%. In another experiment, however, the proportion of positive clones was considerably lower (about 0.2%). In a third experiment the hybrid population was studied by limiting dilution analysis. From 157 independent hybrids, as many as 15 had anti-SRBC activity. The proportion of positive over negative clones is remarkably high. It is possible that spleen cells which have been triggered during immunisation are particularly successful in giving rise to viable hybrids. It remains to be seen whether similar results can be obtained using other antigens.

The cells used in this study are all of BALB/c origin and the hybrid clones can be injected into BALB/c mice to produce solid tumours and serum having anti-SRBC activity. It is possible to hybridise antibody-producing cells from different origins<sup>4,5</sup>. Such cells can be grown *in vitro* in massive cultures to provide specific antibody. Such cultures could be valuable for medical and industrial use.

G. KÖHLER  
C. MILSTEIN

MRC Laboratory of Molecular Biology,  
Hills Road, Cambridge CB2 2QH, UK

Received May 14; accepted June 26, 1975.

- 1 Potter, M., *Physiol. Rev.*, **52**, 631-719 (1972).
- 2 Horibata, K., and Harris, A. W., *Expl Cell Res.*, **60**, 61-70 (1970).
- 3 Milstein, C., and Munro, A. J., in *Defence and Recognition* (edit. by Porter, R. R.), 199-228 (MTP Int. Rev. Sci., Butterworth, London, 1973).
- 4 Cotton, R. G. H., and Milstein, C., *Nature*, **244**, 42-43 (1973).
- 5 Schwaber, J. W., and Cohen, E. P., *Proc. natn. Acad. Sci. U.S.A.*, **71**, 2203-2207 (1974).
- 6 Littlefield, J. W., *Science*, **145**, 709 (1964).
- 7 Svastil, J., and Milstein, C., *Biochem. J.*, **128**, 427-444 (1972).
- 8 Milstein, C., Adetugbo, K., Cowan, N. J., and Secher, D. S., *Progress in Immunology*, **11**, 1 (edit. by Brent, L., and Holborow, J.), 157-168 (North-Holland, Amsterdam, 1974).
- 9 Harris, H., and Watkins, J. F., *Nature*, **205**, 640-646 (1965).
- 10 Awdeh, A. L., Williamson, A. R., and Askonas, B. A., *Nature*, **219**, 66-67 (1968).
- 11 Milstein, C., Brownlee, G. G., Cartwright, E. M., Jarvis, J. M., and Proudfoot, N. J., *Nature*, **252**, 354-359 (1974).
- 12 Frangione, B., and Milstein, C., *Nature*, **244**, 397-399 (1969).
- 13 Jerne, N. K., and Nordin, A. A., *Science*, **140**, 405 (1963).
- 14 Cotton, R. G. H., Secher, D. S., and Milstein, C., *Eur. J. Immunol.*, **3**, 135-140 (1973).